- iSpecimen Inc (NASDAQ:ISPC) has added new global biospecimen suppliers to its proprietary Marketplace platform for advancing oncology and cardiovascular disease research.
- The new suppliers include a cancer-focused biobank in the U.S., which contains a differentiated range of pre-and post-treatment tissue and biofluids across multiple cancer types.
- These samples provide rich genetic, treatment, follow-up, and outcome information.
- Additionally, iSpecimen has retained a European biobank with a vast urine and blood sample inventory from healthy participants aged 45 to 75, collected with participant health data generated from questionnaires and disease diagnoses.
- This biobank contains vital early-onset cancer and cardiovascular disease samples, as well.
- iSpecimen offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers with access to patients and specimens needed for medical discovery.
- Price Action: ISPC shares are up 21.50% at $2.88 during the market session on the last check Thursday.
Cramer Says These 3 Financial Stocks Can Be ‘Tremendous Performers’ If Fed Decides to End Pain Next Year
Prominent market commentator Jim Cramer on Tuesday spoke about three financial stocks which he believes are worth buying.
